The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1275 articles
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) is probing peptide clinics for unlawful health claims on experimental therapies. A Guardian investigation uncovered websites touting benefits like tissue repair from BPC-157 despite scant human evidence. Clinics defend their practices amid rising interest in these injections.
Peptides are short amino acid chains hailed by influencers for weight loss, injury repair, and anti-aging, but is the hype backed by evidence? While approved drugs like Wegovy (semaglutide) show real benefits, unregulated peptides like BPC-157 lack human trials and raise safety flags from experts. Dive into the facts on peptides' potential and pitfalls.
Fitness enthusiasts and longevity experts are raving about Retatrutide, the new triple-agonist weight-loss peptide dubbed 'the ultimate good' by influencers. Outshining GLP-1 drugs like Ozempic, it targets three receptors for superior fat reduction. As phase 3 trials advance toward FDA approval, here's why it's generating massive buzz.
The FDA has approved Foundayo weight loss pill from Eli Lilly on April 1 (ET), introducing a flexible oral GLP-1 option for adults with obesity or weight-related conditions—no food or water restrictions needed. Trial data shows superior weight loss over Rybelsus, averaging 15-20 pounds vs. 8-11 pounds in diabetes patients. This approval sets up a new showdown in the GLP-1 market dominated by injections like Wegovy and Zepbound.
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) is investigating peptide clinics for making bold health claims about unregulated therapies. Clinics promote peptides like BPC-157 for injury recovery and MOTS-C for energy, despite scant human evidence. This Guardian-revealed probe highlights risks in the booming peptide market.
Peptides are short amino acid chains hailed by influencers for wellness benefits like injury repair and weight loss, but many lack human evidence. From approved drugs like semaglutide in Wegovy to unregulated options like the 'Wolverine stack' of BPC-157 and TB-500, we examine the science, legality, and risks in the UK.
The NHS has expanded free Wegovy access to 1.2 million more people, but a doctor is urging caution over a 'miserable' side effect: constipation. Dr. Suraj Kukadia explains how GLP-1 medications like Wegovy slow digestion, leading to this common issue. Discover the mechanism and tips for those considering these weight loss jabs.
The rise of Ozempic and similar GLP-1 medications is dramatically altering dining out habits across America, with users ordering less food and leaving meals uneaten. Restaurants face revenue pressures as customers skip courses and reduce alcohol intake. Forward-thinking spots are introducing smaller portions and tapas-style menus to adapt.
Emerging research is raising questions about GLP-1 weight-loss drugs like Ozempic and Wegovy, showing a potential link to bone loss and fractures in older adults. A major study in the Journal of Clinical Endocrinology & Metabolism found higher fragility fracture risks among seniors on these medications. Experts stress monitoring and preventive steps to balance benefits with bone protection.
